| Literature DB >> 17192706 |
Abstract
The treatment of osteoarthritis (OA) continues to be a challenge, and current treatment modalities are disappointing. New approaches in therapy may be developed as a result of evidence of the involvement of inflammatory cytokines in the progression of OA. Cotrimoxazole (sulfamethoxazole/trimethoprim) was noted to have anti-inflammatory properties and has been used in the therapy of several autoimmune diseases. Analyzing our own and world experience, we propose that OA and degenerative joint and spine disease might be infection-associated diseases and a target for sulfamethoxazole/trimethoprim therapy. Copyright 2007 S. Karger AG, Basel.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17192706 DOI: 10.1159/000098243
Source DB: PubMed Journal: Chemotherapy ISSN: 0009-3157 Impact factor: 2.544